Vaxart Inc., a biotechnology company, is considering implementing a reverse stock split to regain compliance with Nasdaq listing requirements ahead of a June 30, 2025, deadline. The company aims to address its stock price challenges and maintain its Nasdaq listing by potentially adjusting the number of its outstanding shares. This move is part of Vaxart's strategy to support its capital-raising efforts necessary for vaccine development.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vaxart Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-25-018648), on May 28, 2025, and is solely responsible for the information contained therein.